SEC Filings
Sol-Gel Has $45.7 Million To Fund Development Into Early 2028, It Expects
The skin-drug developer expects late-November trial results and intends to retain U.S. rights if its lead treatment wins approval.
Sol-Gel Technologies (SLGL) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The skin-drug developer expects late-November trial results and intends to retain U.S. rights if its lead treatment wins approval.
SEC Filings
Trails Edge Capital and its chief investment officer hold 166,473 Sol-Gel shares through a Cayman fund, a filing shows.